Partner contact: Ismail Labgaa
EPFL laboratory: Machine Learning and Optimization Laboratory (MLO), intelligent Global Health Research group
EPFL contact: Mary-Anne Hartley
Liver cancer is the second deadliest malignancy. It essentially accounts hepatocellular carcinoma (HCC). Surgery with liver resection is the main curative option but unfortunately, it is only recommended in patients with early HCC. The current guidelines for the allocation of treatments relies on the Barcelona Liver Cancer Clinic (BCLC) algorithm which role is highly debated. Prognosis of HCC is particularly challenging and results from numerous attempts using various strategies remain relatively poor.
Artificial intelligence (AI) has demonstrated unmatched value to decipher complex traits and mechanisms. To date, its application for HCC prognostication is unknown.
This multicentric effort will include 8 Academic centers from the United States, Europe and Asia, allowing to generate a large-scale dataset of patients undergoing liver resection for HCC. We aim to investigate the input of AI to improve prognostication of these patients, which may have important impact on treatments selection and ultimately on their outcomes.